AlbionVC

AlbionVC is a London-based venture capital firm established in 1996, specializing in seed to series B investments. The firm focuses on a range of sectors, including healthcare, digital health, medtech, B2B software, SaaS, digital risk, fintech, artificial intelligence, deep tech, and life sciences. AlbionVC typically invests between £0.25 million and £10 million, supporting early-stage companies with long-term capital and expertise to help them scale. As a subsidiary of Albion Capital Group LLP, AlbionVC is authorized and regulated by the Financial Conduct Authority and is actively involved in over 50 companies within its investment portfolio.

Leigh Brody

Investment Manager

Andrew Elder

Deputy Managing Partner

Lehair, Paul

Investment Director

Cat McDonald

Investment Manager

Robert Whitby Smith

Partner

Nadine Torbey

Investment Manager

Jay Wilson

Investment Director

Pauline Stasiak Ph.D

Investment Manager

106 past transactions

Accelex

Series A in 2022
Accelex allows investors and servicers in alternative assets to quickly and easily acquire, extract and analyze investment data. Using artificial intelligence and machine learning, Accelex allows clients to automate the accessing, extracting, organizing and analyzing of data from alternative investment portfolios. This offers clients a more complete picture of investments from the overall portfolio all the way down to the underlying assets.

Black Swan Data

Venture Round in 2022
Black Swan Data produces a social prediction SaaS platform. They use AI tech to curate various conversations into a framework for growth. The company uses AI, deep learning, and NLP techniques to transform this raw content into accessible predictive insight for subscribers.

Ophelos

Seed Round in 2022
Ophelos was created to transform how individuals, families, and businesses manage their financial health.

Speechmatics

Series B in 2022
Speechmatics exists to understand every voice. Offering its speech-to-text API engine for solution and service providers to integrate into their stack irrespective of their industry or use case. Businesses use Speechmatics around the world to accurately understand and transcribe human-level speech into text regardless of demographic, age, gender, accent, dialect or location

uMotif

Series B in 2022
UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceutical companies to capture rich health data across a range of conditions.

Regulatory Genome

Seed Round in 2022
Regulatory Genome provides dynamic, granular, and interoperable machine-readable regulatory content powered by AI-based textual information extraction techniques. Regulatory Genome enables regulatory authorities to improve the accessibility and dissemination of regulatory information, while also enabling organizations to deepen their regulatory intelligence and digitize their compliance and risk management processes. RegGenome content is vendor-neutral, allowing it to be integrated into any application or system, allowing for the creation of an efficient ecosystem of providers and users.

TransFICC

Venture Round in 2022
TransFICC is an e-trading technology company providing low latency connectivity for banks and asset managers trading in Fixed Income and Derivatives markets. The company resolves the problem of fragmentation in the fixed income and derivatives markets. It does three things such as translates Execution Venue API’s to a single API. Clients connect once to TransFICC's unified API, and TransFICC manages connectivity with the electronic venues from that point, uses low-latency, scalable and secure technology, essential to keep pace with price updates and not get beaten to trade by high-frequency trading firms, and provides timestamps for price and order messages. Measured in microseconds, timestamps record when data arrives at the bank or asset manager, helping to provide an audit trail, which supports Best Execution. TransFICC makes it easier to upgrade when venues change their application programming interfaces, compared with the enterprise systems of legacy firms, the firm claims. It also focuses solely on the business of providing market access. TransFICC was founded in 2016 and is based in London, England, United Kingdom.

PerchPeek

Series A in 2022
PerchPeek uses AI to guide people through every stage of their relocation from search to settling in. It serves as an AI-powered home search assistant that makes it easier for flat-hunters to find a new home. The company was founded in 2017 and based in London, England.

brytlyt

Series A in 2021
Brytlyt is the world’s first all-in-one browser-led platform that enables GPU in-database AI with deep learning capabilities. We aim to empower the next generation of data scientists and decision makers with accessible deep learning methods and data analytics at GPU speeds.

Elliptic

Series C in 2021
Elliptic makes cryptocurrency transaction activity more transparent and accountable.They believe that illicit activity in cryptocurrencies must be disrupted to stop criminals from undermining the ideals on which cryptocurrencies are built. This is their focus, and they do this by solving the crucial problem of identity in cryptocurrencies, with the sole purpose of combating suspicious and criminal activity. Their team pushes the limits to dig beneath the surface, peeling back the layers to expose the truth. They aim to stop illicit cryptocurrency activity from leaving a smudge on the technology and the future it represents for all of them. The company is preventing, detecting, and pursuing criminal activity in cryptocurrencies. It identifies illicit activity in cryptocurrencies, providing actionable intelligence to cryptocurrency companies, financial institutions and government agencies.

Imandra

Seed Round in 2021
Imandra specializes in cloud-scale automated reasoning. Its platform is designed to deliver rigor and governance to the world's most critical algorithms. The company was founded in 2014 and is headquartered in Austin, Texas.

Oviva

Series C in 2021
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform. They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allows patients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions. Oviva was founded in 2013 and is based in London, England.

Gravitee

Series A in 2021
Gravitee is an API management platform that helps organizations secure, build, monitor, and manage their API lifecycle. The platform offers API development, security, management, observability, and productization within one intelligent platform. The company's identity and access management is an easy-to-use, free, open-source solution to effortlessly secure applications and APIs through authentication and authorization. Gravitee was founded in 2015 and is based in Lille, Hauts-de-France.

Quantexa

Series D in 2021
Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.

NuvoAir

Series A in 2021
NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient's journey is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes.

Accelex

Seed Round in 2021
Accelex allows investors and servicers in alternative assets to quickly and easily acquire, extract and analyze investment data. Using artificial intelligence and machine learning, Accelex allows clients to automate the accessing, extracting, organizing and analyzing of data from alternative investment portfolios. This offers clients a more complete picture of investments from the overall portfolio all the way down to the underlying assets.

Healios

Series A in 2021
Founded in 2013, Healios is a leading digital healthcare technology company working to empower patients and families affected by mental and physical illnesses.Healios is pioneering how family intervention and behavioural change techniques are delivered beyond treatment team walls, to maximise patient and family outcomes. By blending the best of technology, specialised expertise and a personal human connection, they help patients and families develop a new level of understanding and sustain healthier habits over time. Their mission is to transform how care is delivered to help patients, families and carers effectively move forward and achieve their goals, providing a better quality of life.

Panaseer

Series B in 2021
Panaseer is the first Continuous Controls Monitoring platform for enterprise cybersecurity. Our platform shows you every asset, application, user and data set across your IT estate in real-time. This identifies gaps in controls coverage, aligns security with framework standards and substantiates regulatory compliance. Our automated reports significantly reduce reporting time and tailor insights to stakeholders at every level, enhancing decision-making from the boardroom to the analyst. These reports can also be mapped to the organisation’s structure, so you can prioritise risk based on impact to the business. Enterprise security leaders around the world trust our platform to help them make better security decisions.

Solidatus

Series A in 2021
Award-winning Solidatus is the leading next generation data lineage and conceptual modelling solution that effectively manages meta data, data and processes. It has solidified its place as one of the most influential and critical new software solutions positioned to help the world’s largest data-rich and regulated organisations manage their processes and data. It highlights gaps, declares transparency and provides a simpler, quicker and better route to implement change. Critically it also validates the integrity of AI generated data Solidatus facilitates both data lineage and business process engineering. Whether to demonstrate regulatory compliance, improve governance, assist with transformational change or optimise your data landscape, it builds a connected digital map of your organisation, reducing complexity while driving efficiency. It is uniquely engineered to build end-to-end data models more efficiently and effectively and improve an organisation’s data economy. Solidatus is quickly being adopted by organisations across the globe, including top-tier global financial, pharmaceutical, utility and infrastructure firms and has been implemented by leading consulting and technology firms. Solidatus is headquartered in London, UK with an office in Singapore. Planned expansion into the US, Europe and the Middle East scheduled for 2021.

Limitless

Series B in 2021
Limitless enables businesses to connect customers with qualified experts to solve customer service enquiries on-demand, providing a faster and better service for significantly less cost. Expert responses and customer feedback then train our AI systems to automate low value queries overtime. The platform is live in over 20 countries and major clients include Microsoft, Unilever and Sage. Current investors include Unilever Ventures, Downing Ventures and Albion Capital.

Umedeor

Seed Round in 2020
uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access to regulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams

Runa

Series A in 2020
Runa is pioneering a first-of-its-kind payment rail capable of sending and accepting digital value at scale. With Runa, companies can pay the people they serve in any form of digital value, anywhere, instantly. The Runa Network provides a wide range of digital payout types including gift cards, prepaid cards, subscriptions, donations, cryptocurrencies and more. Legacy payment mechanisms struggle to adapt to low-volume, high-velocity transactions both locally and globally, such as sending payouts to gig workers, creators, or sending rewards to customers or employees wherever they are. Runa’s infrastructure and network facilitates payouts to these recipients, helping businesses expand their reach, retain their users while modernizing the way in which they manage and transfer money: instantly, internationally, and free of charge for the senders and the recipient. Runa was established as WeGift in October 2016 by Aron Alexander in London, England.

Seldon

Series A in 2020
Seldon enables ml engineering teams to accelerate from r and d to production with proven efficiency gains. Its customers include large enterprises across sectors and geographies, including leaders in technology, pharma, automotive, finance, and retail. Their open-source projects are considered in model serving, explanations, and monitoring with installs and models deployed.

uMotif

Series A in 2020
UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceutical companies to capture rich health data across a range of conditions.

Quantexa

Series C in 2020
Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.

TransFICC

Series A in 2020
TransFICC is an e-trading technology company providing low latency connectivity for banks and asset managers trading in Fixed Income and Derivatives markets. The company resolves the problem of fragmentation in the fixed income and derivatives markets. It does three things such as translates Execution Venue API’s to a single API. Clients connect once to TransFICC's unified API, and TransFICC manages connectivity with the electronic venues from that point, uses low-latency, scalable and secure technology, essential to keep pace with price updates and not get beaten to trade by high-frequency trading firms, and provides timestamps for price and order messages. Measured in microseconds, timestamps record when data arrives at the bank or asset manager, helping to provide an audit trail, which supports Best Execution. TransFICC makes it easier to upgrade when venues change their application programming interfaces, compared with the enterprise systems of legacy firms, the firm claims. It also focuses solely on the business of providing market access. TransFICC was founded in 2016 and is based in London, England, United Kingdom.

Concirrus

Series B in 2020
Concirrus is a leading Insurtech specialising in transforming the future of risk selection, pricing and claims using the latest developments in data analytics, AI, machine learning, and digitalisation. Concirrus' intelligence platform Quest, helps organisations improve loss ratios, reduce operational expense and access increased deal sizes, and new trading relationships. By capturing and understanding customer behaviour, delivering data-rich insights at scale, underwriting teams are empowered to make rapid data-driven decisions. Over 20 market-leading companies including Marsh, Beazley, Hiscox, Chaucer and Willis Re trust Concirrus’ technology to power their risk making decisions. Headquartered in London with international presence, Concirrus has a 100-strong team of experts that specialise in data analytics, AI and machine learning, as well as having a rich understanding of the global insurance market.

Hazy

Seed Round in 2020
Data has never been more valuable. But with growing privacy demands and tightening regulations, most of the world’s data is locked away and unusable. For businesses to make better decisions, develop new technologies and deliver more value for customers, they need data they can actually use. They need to set their data free to do more. Hazy is pioneering the new data. We’re the world’s leading synthetic data company, re-engineering enterprise data so that it can be: - Shared without restrictions - data that can move freely, without restriction, to where it’s needed most in businesses and society - Used without limits - data that’s reliable, safe and easy for people and businesses to use to solve problems and create new value. - Trusted without question - data that’s open, transparent and trusted by people, businesses and society.

Hussle

Series A in 2020
Hussle provides fitness, marketplaces, online, digital, marketing, gym, advertising, and membership services. They also provide a network of gyms, pools, spas, and health fitness apps.

Oviva

Series B in 2020
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform. They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allows patients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions. Oviva was founded in 2013 and is based in London, England.

Speechmatics

Series A in 2019
Speechmatics exists to understand every voice. Offering its speech-to-text API engine for solution and service providers to integrate into their stack irrespective of their industry or use case. Businesses use Speechmatics around the world to accurately understand and transcribe human-level speech into text regardless of demographic, age, gender, accent, dialect or location

Elliptic

Series B in 2019
Elliptic makes cryptocurrency transaction activity more transparent and accountable.They believe that illicit activity in cryptocurrencies must be disrupted to stop criminals from undermining the ideals on which cryptocurrencies are built. This is their focus, and they do this by solving the crucial problem of identity in cryptocurrencies, with the sole purpose of combating suspicious and criminal activity. Their team pushes the limits to dig beneath the surface, peeling back the layers to expose the truth. They aim to stop illicit cryptocurrency activity from leaving a smudge on the technology and the future it represents for all of them. The company is preventing, detecting, and pursuing criminal activity in cryptocurrencies. It identifies illicit activity in cryptocurrencies, providing actionable intelligence to cryptocurrency companies, financial institutions and government agencies.

Koru Kids

Series A in 2019
Koru Kids is a building better childcare services, starting with nanny sharing in London. The team behind Koru Kids has a background in childcare (their own and other people's), healthcare and tech startups. Their company name is Koru Kids, company number is 10047637, and their HQ is 110 Hampstead Road, London, NW1 2LS. 'Koru Kids' is a registered trademark (UK00003153316). They are registered with the Information Commissioners' Office (registration number ZA181818), and also affiliated with the Financial Conduct Authority's Innovation Hub. They are grateful for the ongoing support (financial and moral!) of Camden Council.

Clear Review

Series A in 2019
Clear Review is an ongoing performance management solution that runs in the cloud and is built around thoughtful discussions and feedback. The company is passionate about equipping human resources professionals and empowering employees to bring their best selves to work. Clear Review has a distinct vision for how to motivate performance improvement, and it is striking a chord with local HR and talent executives.

Symetrica

Venture Round in 2019
Symetrica Ltd. engages in the development and commercialization of radiation detection and identification systems for security, medical diagnostics, geophysical, and space research and development applications. The company was incorporated in 2002 and is based in Southampton, the United Kingdom.

Astroscreen

Seed Round in 2019
Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing.

Imandra

Seed Round in 2019
Imandra specializes in cloud-scale automated reasoning. Its platform is designed to deliver rigor and governance to the world's most critical algorithms. The company was founded in 2014 and is headquartered in Austin, Texas.

Limitless

Series A in 2019
Limitless enables businesses to connect customers with qualified experts to solve customer service enquiries on-demand, providing a faster and better service for significantly less cost. Expert responses and customer feedback then train our AI systems to automate low value queries overtime. The platform is live in over 20 countries and major clients include Microsoft, Unilever and Sage. Current investors include Unilever Ventures, Downing Ventures and Albion Capital.

Avora

Series A in 2019
We help everyone work smarter. By removing unnecessary boundaries and giving everyone access to insights, we help people accelerate decision making and drive positive change, every day. Avora provides a complete augmented analytics solution powered by AI that makes in-depth data analysis as easy as a web search. Our unique technology hides complexity, empowering non-technical users to easily run and share their own reports. By eliminating the limitations of existing analytics, reducing data preparation and discovery time by 50-80%, and accelerating time to insight to just a matter of minutes rather than days, Avora uses Machine Learning to improve business insight, accuracy and performance. Headquartered in London with offices in New York and Romania, Avora helps accelerate decision making and productivity for customers across a range of industries and markets, including Retail, Financial Services, Advertising, Supply Chain and Media and Entertainment.

Egress Software

Series C in 2018
Egress is a software company that specializes in human layer security designed to prevent accidental and intentional data breaches. Its mission is to eliminate the greatest risk to every business the insider threat. To achieve this Egress has built the world’s only Human Layer Security platform that empowers your people to remain secure while being highly productive.

Epsilogen

Series A in 2018
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Xperiome

Series A in 2018
Raremark builds online communities in rare, medical conditions so patients and their families can learn from the experiences of others like them, participate in clinical trials, and share their experience of new treatments. The company's vision is a world in which all rare conditions are treated.

Pando

Seed Round in 2018
Pando is an essential tool for teamwork and secure collaboration. It is designed to benefit anyone working in health and social care, working in a team, with a need to share sensitive information and images securely.

Locum's Nest

Venture Round in 2018
Locum's Nest is an award-winning software platform connecting healthcare professionals to vacant work through innovative technology. The concept of Locum’s Nest originated from our Co-Founders, Dr Ahmed Shahrabani and Dr Nicholas Andreou, who had the determination and conviction to solve the staffing puzzle for professionals and organisations alike whilst they worked on the front line - as Junior Doctors. They experienced first-hand how hospitals and practices had to dedicate so much time in arranging cover to resource patient care, and not forgetting the drain it proved on precious, limited finances. We have a passion for best in class software engineering, with a team full of diverse talent, skills and expertise. To complement our product, we focus on long term partnerships with our customers, having a dedicated team on hand with a variety of NHS experiences. But, for any product to be truly effective, we must understand our app users and make it accessible. This requires a constant cycle of thinking, testing, building and learning.

Arecor

Venture Round in 2018
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Phrasee

Series A in 2018
Phrasee is AI that specialises in language generation for marketing copy. Phrasee has developed a world-leading Natural Language Generation system, that can generate millions of human-sounding variants at the touch of a button. Phrasee’s tailored algorithms are created to target your customers, ensuring the copy Phrasee generates is on-point for your brand. The results? More opens, clicks, and conversions. Awesome. Having studied millions of words, phrases, and sentences, They’ve proven there is a science to human language. They designed Phrasee to use artificial intelligence to generate marketing language that outperforms humans. And it works – awesomely. Phrasee began as an idea in a pub in Camden Town, London, over a pale ale or three. Now it’s all over the internet. And is revolutionizing digital marketing, one sentence at a time.

Quantexa

Series B in 2018
Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.

Hazy

Seed Round in 2018
Data has never been more valuable. But with growing privacy demands and tightening regulations, most of the world’s data is locked away and unusable. For businesses to make better decisions, develop new technologies and deliver more value for customers, they need data they can actually use. They need to set their data free to do more. Hazy is pioneering the new data. We’re the world’s leading synthetic data company, re-engineering enterprise data so that it can be: - Shared without restrictions - data that can move freely, without restriction, to where it’s needed most in businesses and society - Used without limits - data that’s reliable, safe and easy for people and businesses to use to solve problems and create new value. - Trusted without question - data that’s open, transparent and trusted by people, businesses and society.

uMotif

Venture Round in 2018
UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceutical companies to capture rich health data across a range of conditions.

Panaseer

Series A in 2018
Panaseer is the first Continuous Controls Monitoring platform for enterprise cybersecurity. Our platform shows you every asset, application, user and data set across your IT estate in real-time. This identifies gaps in controls coverage, aligns security with framework standards and substantiates regulatory compliance. Our automated reports significantly reduce reporting time and tailor insights to stakeholders at every level, enhancing decision-making from the boardroom to the analyst. These reports can also be mapped to the organisation’s structure, so you can prioritise risk based on impact to the business. Enterprise security leaders around the world trust our platform to help them make better security decisions.

Healios

Venture Round in 2018
Founded in 2013, Healios is a leading digital healthcare technology company working to empower patients and families affected by mental and physical illnesses.Healios is pioneering how family intervention and behavioural change techniques are delivered beyond treatment team walls, to maximise patient and family outcomes. By blending the best of technology, specialised expertise and a personal human connection, they help patients and families develop a new level of understanding and sustain healthier habits over time. Their mission is to transform how care is delivered to help patients, families and carers effectively move forward and achieve their goals, providing a better quality of life.

Hussle

Series A in 2018
Hussle provides fitness, marketplaces, online, digital, marketing, gym, advertising, and membership services. They also provide a network of gyms, pools, spas, and health fitness apps.

Koru Kids

Seed Round in 2018
Koru Kids is a building better childcare services, starting with nanny sharing in London. The team behind Koru Kids has a background in childcare (their own and other people's), healthcare and tech startups. Their company name is Koru Kids, company number is 10047637, and their HQ is 110 Hampstead Road, London, NW1 2LS. 'Koru Kids' is a registered trademark (UK00003153316). They are registered with the Information Commissioners' Office (registration number ZA181818), and also affiliated with the Financial Conduct Authority's Innovation Hub. They are grateful for the ongoing support (financial and moral!) of Camden Council.

MeiraGTx

Venture Round in 2017
MeiraGTx is committed to the development and commercialization of innovative gene therapy products to transform the lives of patients suffering from acquired and inherited disorders. The company is dedicated to advancing innovative treatments for patients with serious medical conditions. MeiraGTx's research and development efforts primarily revolve around gene therapy, a cutting-edge approach that involves modifying or replacing faulty genes to treat or prevent diseases. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring, and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland, and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

Oviva

Series A in 2017
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform. They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allows patients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions. Oviva was founded in 2013 and is based in London, England.

Locum's Nest

Venture Round in 2017
Locum's Nest is an award-winning software platform connecting healthcare professionals to vacant work through innovative technology. The concept of Locum’s Nest originated from our Co-Founders, Dr Ahmed Shahrabani and Dr Nicholas Andreou, who had the determination and conviction to solve the staffing puzzle for professionals and organisations alike whilst they worked on the front line - as Junior Doctors. They experienced first-hand how hospitals and practices had to dedicate so much time in arranging cover to resource patient care, and not forgetting the drain it proved on precious, limited finances. We have a passion for best in class software engineering, with a team full of diverse talent, skills and expertise. To complement our product, we focus on long term partnerships with our customers, having a dedicated team on hand with a variety of NHS experiences. But, for any product to be truly effective, we must understand our app users and make it accessible. This requires a constant cycle of thinking, testing, building and learning.

Panaseer

Seed Round in 2017
Panaseer is the first Continuous Controls Monitoring platform for enterprise cybersecurity. Our platform shows you every asset, application, user and data set across your IT estate in real-time. This identifies gaps in controls coverage, aligns security with framework standards and substantiates regulatory compliance. Our automated reports significantly reduce reporting time and tailor insights to stakeholders at every level, enhancing decision-making from the boardroom to the analyst. These reports can also be mapped to the organisation’s structure, so you can prioritise risk based on impact to the business. Enterprise security leaders around the world trust our platform to help them make better security decisions.

MPP Global

Series B in 2017
MPP Global delivers the only fully integrated cloud platform to identify, engage and monetise digital audiences. From metering and profiling to promotions, payments, subscriptions, and analytics, eSuite powers organisations to extract maximum value from their content and embrace monetisation opportunities prevalent in today's digital landscape. Founded in 2000, with offices throughout Europe, U.S., South America, and Australia, MPP Global has an impressive track record of helping companies create successful business models. Clients include Sky, The Times, McClatchy, The Football League, L'Equipe, Racing Post, Daily Mail, Local Media Group, New Zealand Herald, Debenhams, Philips and The Irish Times. For more information about MPP Global, please visit http://www.mppglobal.com

Quantexa

Series A in 2017
Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. The platform helps organizations protect, optimize, and grow by leveraging AI to unify siloed data, identify opportunities, and mitigate fraud. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risks and new opportunities by providing a contextual, connected view of internal and external data in a single place.

Convertr

Series A in 2016
Convertr is an API-first data optimization platform that acts as a firewall. We protect companies against expensive, bloated marketing databases overwhelmed by bad data. As a true SaaS platform, Convertr is not a lead or data provider. We are an unbiased tool, used to filter, enhance, normalize and automatically route compliant, accurate & actionable data to any number of endpoints.

SBD Automotive

Venture Round in 2016
Automotive Research & Consultancy, Connected Car Telematics, Vehicle Security, Autonomous Vehicles & ADAS, Analytical Reports, System Usability Testing, End User Surveys, Industry and Market Forecasts, Technical and Market Trends, Competitor Benchmarking

Achilles Therapeutics

Seed Round in 2016
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Black Swan Data

Series B in 2016
Black Swan Data produces a social prediction SaaS platform. They use AI tech to curate various conversations into a framework for growth. The company uses AI, deep learning, and NLP techniques to transform this raw content into accessible predictive insight for subscribers.

Orchard Therapeutics

Series A in 2016
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

InCrowd Sports

Seed Round in 2016
InCrowd is a combination of three award winning, experienced and highly successful groups from three different sectors within sport, united in the aim to dramatically improve the in-stadia experience for fans, clubs and sponsors. A cutting edge technology solution was first created by the software engineers at the Sussex Innovation Centre led by Ian Wakeman, Jon Rimmer and Ciaran Fisher. Their solution allowed fans within stadiums to share information through a network which wasn’t reliant on multiple 3G/4G connections.

Grapeshot

Series C in 2016
Grapeshot (Acquired by Oracle) empowers the world’s leading brands and advertisers to bring relevance to every customer experience. With its proprietary Contextual Intelligence platform, Grapeshot transforms information into actionable data, and identifies revenue-driving behaviors. With solutions for predictive targeting, brand safety, and audience enrichment, advertisers, media agencies, programmatic platforms and publishers use power of Grapeshot to improve media efficiency, increase customer engagement and boost brand perception with their intended audiences. It has been named “Digiday’s Best Publisher Tool” and “Best Attribution Solution for Keyword Signal,” The Drum’s “Best Attribution Solution,” and the British Media Awards’ “Ad Provider of the Year,” among other honors. Grapeshot entered the market in 2006, and has offices in San Francisco, Los Angeles, Chicago, Toronto, New York, London, Cambridge, Singapore, Hong Kong, Shanghai and Sydney.

Panaseer

Seed Round in 2015
Panaseer is the first Continuous Controls Monitoring platform for enterprise cybersecurity. Our platform shows you every asset, application, user and data set across your IT estate in real-time. This identifies gaps in controls coverage, aligns security with framework standards and substantiates regulatory compliance. Our automated reports significantly reduce reporting time and tailor insights to stakeholders at every level, enhancing decision-making from the boardroom to the analyst. These reports can also be mapped to the organisation’s structure, so you can prioritise risk based on impact to the business. Enterprise security leaders around the world trust our platform to help them make better security decisions.

Hussle

Series A in 2015
Hussle provides fitness, marketplaces, online, digital, marketing, gym, advertising, and membership services. They also provide a network of gyms, pools, spas, and health fitness apps.

Abcodia

Series B in 2015
Abcodia is a biotechnology company that focused on the discovery and validation of biomarkers for cancer screening. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers, and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process. Abcodia was founded in 2010 and is based in Cambridge, UK.

Aridhia Informatics

Venture Round in 2014
Aridhia provides world leading biomedical informatics and analytic solutions to support stratified medicine and translational research, which will enhance understanding, diagnosis, prevention and treatment of chronic diseases. Aridhia believes that the integration and application of patient, clinical and genomic data represents a powerful opportunity to support clinical care across healthcare sectors, provide patients with the ability to take a more active role in their own care and provide information at a population level about disease trends, risk factors, impact of treatment and informed public health programmes. Working in close collaboration with experts in a clinical faculty model, Aridhia’s multidisciplinary team provides a unique combination of expertise to address one of the world’s most pressing health problems.

Exco InTouch

Venture Round in 2014
Exco InTouch focuses on the development of digital engagement and data capture solutions for clinical research and healthcare programs. Exco InTouch offers Gather, a system that enables clinical research providers gain data and improve patient engagement. The company also develops solutions that focus on patients’ long term condition management. Exco InTouch was founded in 2004 by Tim Davis. It is headquartered in Nottingham, England.

Mirada Medical

Venture Round in 2014
Mirada Medical is a prominent global brand in medical imaging software. Mirada’s innovative software solutions are routinely used in radiology, molecular imaging, radiation oncology and in multidisciplinary meetings throughout hospitals, imaging centers and cancer centers worldwide. Mirada excels at combining scientifically advanced technology with practical application for diagnosis, management and treatment of cancer and other diseases. - See more at: http://www.mirada-medical.com/about-mirada-medical/#sthash.Sp4rzAG0.dpuf

Brandgility

Venture Round in 2014
The Brandgility Brand Asset Management (BAM) platform allows organizations to easily store and share brand assets and safely empower their workforce to build sales and marketing collateral with no-code, smart templates, and powerful creative automation tools that automatically comply with brand guidelines. Brandgility is a self-service solution designed to empower your workforce to own and streamline processes with the creation and maintenance of brand assets. With simple integrations available to ensure the cloud-based solution fits seamlessly into your organization. Trusted by some of the world’s leading brands Brandgility brings Brand Asset management to the forefront. Landing more relevant and engaging content across an expanding array of channels is driving big gains for savvy marketers. 30%-40%+ improvements in target outcomes, including customer acquisition, up-sales, registrations & referrals are not uncommon, along with improved brand affinity & loyalty. On the other hand, relevant, multi-channel engagement requires orders of magnitude more content. As a result, promising gains are too often obliterated by ballooning costs.

Abcodia

Venture Round in 2014
Abcodia is a biotechnology company that focused on the discovery and validation of biomarkers for cancer screening. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers, and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process. Abcodia was founded in 2010 and is based in Cambridge, UK.

MyMeds&Me

Venture Round in 2014
MyMeds&Me Ltd was formed in 2011 by Dr Andrew Rut, Dr Trevor Gibbs and Steve Powell. The founders bring together a unique blend of pharmaceutical and commercial experience, encompassing leadership of global clinical development, safety & pharmacovigilance operations, and the development and global commercialization of technology solutions for the life sciences industry. The strength of this leadership and the business case to create an industry-wide technology solution, led to significant funding being obtained from within the pharmaceutical industry itself and private equity during 2012/13.

Perpetuum

Series C in 2014
Perpetuum Ltd. specializes in the engineering, manufacturing, and commercialization of electromagnetic vibration harvesting micro generators. Founded in 2004 and based in Southampton, United Kingdom, the company focuses on creating battery-free vibration energy harvesters and wireless sensor nodes for various applications, including rail, oil and gas, chemicals, power generation, and water treatment. Perpetuum's technology converts mechanical vibrations into electrical energy, enabling autonomous, maintenance-free wireless sensors that monitor equipment conditions and processes. This innovative approach enhances efficiency and safety in fleet management and services, particularly within the rail industry. As a technology spin-off from the University of Southampton, Perpetuum has established itself as a leader in vibration energy harvesting, providing practical solutions for wireless automation.

Proveca

Venture Round in 2014
Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit from a period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently. Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.

Cisiv

Venture Round in 2014
Cisiv has been a pioneering developer of technology solutions for pharmaceutical companies, enabling customers to capture new levels of information on the use of their products and treatments in real world settings.

OmPrompt

Venture Round in 2014
OmPrompt’s Order Management Platform provides EDI connectivity, non-EDI document automation, visibility and control solutions in order-to-cash and procure-to-pay processes. With one platform, suppliers can connect to any trading partner, automate any document and process any format.

Blackbay

Venture Round in 2014
Blackbay Ltd. develops and implements mobile enterprise solutions and services for supply chain and field service operations. It offers Delivery Connect, a mobile freight solution for real time job tracking; Service Connect, a business mobility solution that provides off-site service and parts ordering system with timesheets as well as provides vehicle cradles that hold handheld computer devices in vehicles. The company offers its products for use with handheld intelligent devices and the back-end infrastructure in postal, point to point courier, hub and spoke, third party logistics, service dispatch, social housing, facilities management, and manufacturing industries. Blackbay currently has over 55,000 mobile workers in the field worldwide. Customers include Royal Mail, Hermes, Dyson, DHL, DPD, Tyco, Chubb, Konica Minolta, Australia Post, Star Track Express and Capita. Blackbay Ltd. was formerly known as iTouch Business Mobility. The company was founded in 2004 and is headquartered in London, the United Kingdom. Blackbay Ltd. is a former subsidiary of iTouch plc.

Brandgility

Venture Round in 2014
The Brandgility Brand Asset Management (BAM) platform allows organizations to easily store and share brand assets and safely empower their workforce to build sales and marketing collateral with no-code, smart templates, and powerful creative automation tools that automatically comply with brand guidelines. Brandgility is a self-service solution designed to empower your workforce to own and streamline processes with the creation and maintenance of brand assets. With simple integrations available to ensure the cloud-based solution fits seamlessly into your organization. Trusted by some of the world’s leading brands Brandgility brings Brand Asset management to the forefront. Landing more relevant and engaging content across an expanding array of channels is driving big gains for savvy marketers. 30%-40%+ improvements in target outcomes, including customer acquisition, up-sales, registrations & referrals are not uncommon, along with improved brand affinity & loyalty. On the other hand, relevant, multi-channel engagement requires orders of magnitude more content. As a result, promising gains are too often obliterated by ballooning costs.

Mirada Medical

Venture Round in 2014
Mirada Medical is a prominent global brand in medical imaging software. Mirada’s innovative software solutions are routinely used in radiology, molecular imaging, radiation oncology and in multidisciplinary meetings throughout hospitals, imaging centers and cancer centers worldwide. Mirada excels at combining scientifically advanced technology with practical application for diagnosis, management and treatment of cancer and other diseases. - See more at: http://www.mirada-medical.com/about-mirada-medical/#sthash.Sp4rzAG0.dpuf

Grapeshot

Venture Round in 2014
Grapeshot (Acquired by Oracle) empowers the world’s leading brands and advertisers to bring relevance to every customer experience. With its proprietary Contextual Intelligence platform, Grapeshot transforms information into actionable data, and identifies revenue-driving behaviors. With solutions for predictive targeting, brand safety, and audience enrichment, advertisers, media agencies, programmatic platforms and publishers use power of Grapeshot to improve media efficiency, increase customer engagement and boost brand perception with their intended audiences. It has been named “Digiday’s Best Publisher Tool” and “Best Attribution Solution for Keyword Signal,” The Drum’s “Best Attribution Solution,” and the British Media Awards’ “Ad Provider of the Year,” among other honors. Grapeshot entered the market in 2006, and has offices in San Francisco, Los Angeles, Chicago, Toronto, New York, London, Cambridge, Singapore, Hong Kong, Shanghai and Sydney.

Hussle

Venture Round in 2014
Hussle provides fitness, marketplaces, online, digital, marketing, gym, advertising, and membership services. They also provide a network of gyms, pools, spas, and health fitness apps.

Egress Software

Series A in 2014
Egress is a software company that specializes in human layer security designed to prevent accidental and intentional data breaches. Its mission is to eliminate the greatest risk to every business the insider threat. To achieve this Egress has built the world’s only Human Layer Security platform that empowers your people to remain secure while being highly productive.

Abcodia

Venture Round in 2014
Abcodia is a biotechnology company that focused on the discovery and validation of biomarkers for cancer screening. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers, and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process. Abcodia was founded in 2010 and is based in Cambridge, UK.

Cisiv

Venture Round in 2013
Cisiv has been a pioneering developer of technology solutions for pharmaceutical companies, enabling customers to capture new levels of information on the use of their products and treatments in real world settings.

MyMeds&Me

Venture Round in 2013
MyMeds&Me Ltd was formed in 2011 by Dr Andrew Rut, Dr Trevor Gibbs and Steve Powell. The founders bring together a unique blend of pharmaceutical and commercial experience, encompassing leadership of global clinical development, safety & pharmacovigilance operations, and the development and global commercialization of technology solutions for the life sciences industry. The strength of this leadership and the business case to create an industry-wide technology solution, led to significant funding being obtained from within the pharmaceutical industry itself and private equity during 2012/13.

Proveca

Venture Round in 2013
Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit from a period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently. Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.

Hussle

Seed Round in 2013
Hussle provides fitness, marketplaces, online, digital, marketing, gym, advertising, and membership services. They also provide a network of gyms, pools, spas, and health fitness apps.

Workshare

Debt Financing in 2012
Workshare’s innovative and intelligent platform empowers professionals to compare, protect and share their high stakes documents on any device. Content owners can accurately track and compare amendments made by all contributors. While businesses have secure ways to work collaboratively and control the process of constant change. Headquartered in the UK, in London, Workshare also operates offices in the US and Australia. More than two million professionals in 70 countries now use Workshare solutions on their desktop, mobile or tablet. For more information visit www.workshare.com or follow @Workshare on Twitter.

Atego

Venture Round in 2012
Atego is a global software tools and professional services company focused on helping organizations engineer complex, mission- and safety-critical systems and software. Atego has more than 30 years experience in delivering solutions for the world’s largest engineering companies developing complex systems and software for Real-time, Embedded and Mission/Safety Critical applications. These companies are involved in; aerospace & defense, automotive & rail, energy & utilities as well as automation, medical and the electronics industries. Atego pioneered the creation and delivery of standard’s based solutions for UML, SysML, UPDM, Ada, Real-time Java and is actively involved with global standards bodies for systems engineering and software development. Many of our current customers have been using our products and services for decades and continue to rely on Atego’s superior engineering talent and support team dedication.

Abcodia

Venture Round in 2011
Abcodia is a biotechnology company that focused on the discovery and validation of biomarkers for cancer screening. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers, and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process. Abcodia was founded in 2010 and is based in Cambridge, UK.

Celoxica

Venture Round in 2011
Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Oxsensis

Series C in 2010
Oxsensis Ltd. manufactures optical sensors for pressure, vibration, temperature, and multiple parameters. The company offers optical instrumentation for precision controls in various environments, such as car and aero engines, as well as industrial, electrical, nuclear, and space applications. It also provides hi-temp optics, optical MEMS, fiber-optic assemblies, and packaging solutions. The company’s products comprise Wave-Phire Dynamic Pressure Transducer, which is used in harsh atmospheres, such as gas turbines and other combustion environments; i-Phire 4 Channel Optical Interrogator Unit that converts the optical signal into a voltage signal, which is directly proportional to the dynamic pressure; and S-Phire, a software for combustion monitoring. It serves energy production and emissions monitoring, transport, and high temperature equipment health monitoring markets. The company was incorporated in 2003 and is based in Didcot, the United Kingdom.

Opta

Venture Round in 2008
Opta Sportsdata Limited is a sports data company that collects, packages, analyses, and distributes live data. The company provides live performance data for broadcasting, betting, media, and professional sports; editorial services; data visualization services; analytical products and services; and data of leagues and competitions. It serves clients in betting, broadcast, online and mobile, and print sectors, as well as clubs and governing bodies, and sponsors and brands worldwide.

Oxsensis

Venture Round in 2007
Oxsensis Ltd. manufactures optical sensors for pressure, vibration, temperature, and multiple parameters. The company offers optical instrumentation for precision controls in various environments, such as car and aero engines, as well as industrial, electrical, nuclear, and space applications. It also provides hi-temp optics, optical MEMS, fiber-optic assemblies, and packaging solutions. The company’s products comprise Wave-Phire Dynamic Pressure Transducer, which is used in harsh atmospheres, such as gas turbines and other combustion environments; i-Phire 4 Channel Optical Interrogator Unit that converts the optical signal into a voltage signal, which is directly proportional to the dynamic pressure; and S-Phire, a software for combustion monitoring. It serves energy production and emissions monitoring, transport, and high temperature equipment health monitoring markets. The company was incorporated in 2003 and is based in Didcot, the United Kingdom.

Process Systems Enterprise

Venture Round in 2007
PSE is the world's leading supplier of Advanced Process Modelling technology and related model-based engineering and innovation services to the process industries. We help our customers to create value in their organisations through the application of advanced process modelling using our gPROMS platform technology. This enables them to explore the process decision space rapidly, reduce uncertainty and make better, faster and safer design and operating decisions through deeper understanding of their processes. The result is accelerated innovation with faster time-to-market, improved process and product design, enhanced operations, more efficient and effective R&D and experimental programmes, and better-managed risk.

memsstar

Venture Round in 2007
Since 2003, memsstar has served as Europe’s premier process and equipment supplier of etch and deposition solutions for semiconductor, MEMS and related technology manufacturing processes. The company innovates best-in-class solutions based on Applied Materials, Lam and Novellus platforms combined with its proprietary memsstar® systems for MEMS applications. memsstar offers full manufacturing, design, process engineering and demo capabilities. ISO 9001 certified, the company is recognized for its remanufacturing excellence, technology development, process guarantees, as well as extensive service capabilities to support its full range of remanufactured semiconductor and proprietary MEMS equipment. How memsstar serves the global MEMS markets: Developed MEMS-dedicated processes for manufacturing using semiconductor equipment OEM for memsstar® tools optimized for MEMS-specific manufacturing

Process Systems Enterprise

Venture Round in 2007
PSE is the world's leading supplier of Advanced Process Modelling technology and related model-based engineering and innovation services to the process industries. We help our customers to create value in their organisations through the application of advanced process modelling using our gPROMS platform technology. This enables them to explore the process decision space rapidly, reduce uncertainty and make better, faster and safer design and operating decisions through deeper understanding of their processes. The result is accelerated innovation with faster time-to-market, improved process and product design, enhanced operations, more efficient and effective R&D and experimental programmes, and better-managed risk.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.